Pfizer and BioNTech announced phase 3 trial data showing high efficacy of booster dose of COVID-19 vaccine
On Oct. 21, 2021, Pfizer and BioNTech announced topline results from a Phase 3 randomized, controlled trial evaluating…
On Oct. 21, 2021, Pfizer and BioNTech announced topline results from a Phase 3 randomized, controlled trial evaluating…
On Oct. 21, 2021, Inovio Pharma announced the signing of a non-binding memorandum of understanding with Colombia’s Ministry…
On Oct. 21, 2021, the National Institutes of Health (NIH) announced that a booster dose of the mRNA-1273…
On Oct. 21, 2021, Ligand Pharmaceuticals announced the signing of a collaboration agreement granting China Resources Double-Crane Pharmaceutical…
On Oct. 21, 2021, Johnson & Johnson announced that the U.S. Centers for Disease Control and Prevention (CDC)…
On Oct. 20, 2021, Moderna announced that the U.S. Food and Drug Administration (FDA) had authorized for emergency…
On Oct. 20, 2021, Johnson & Johnson announced the U.S. Food and Drug Administration (FDA) had issued an…
On Oct. 20, 2021, Quest Diagnostics announced it had formed an agreement with the Texas Department of State…
On Oct. 19, 2021, National Science Foundation funded scientists at the Yale School of Public Health and the…
On Oct. 18, 2021, a clinical trial has found that treatment with the immunomodulator interferon beta-1a plus the…
On Oct. 18, 2021, Valneva, a specialty vaccine company, announced positive topline results from the Phase 3 pivotal…
On Oct. 18, 2021, Gilead Sciences announced that the Food and Drug Administration had approved a new low-dose…
On Oct. 18, 2021, Pfizer and BioNTech announced that the European Medicines Agency’s Committee for Human Medicinal Products…
On Oct. 15, 2021, Merck announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use…
On Oct. 15, 2021, Pfizer and BioNTech announced they had submitted data supporting the vaccination of children 5…
On Oct. 14, 2021, The National Institutes of Health (NIH) Rapid Acceleration of Diagnostics (RADx) initiative announced that…
On Oct. 14, 2021, Moderna confirmed that the U.S. Food and Drug Administration’s (FDA) Vaccines and Related Biological…
On Oct. 14, 2021, the U.S. Department of Agriculture’s Agriculture Research Service (ARS) announced confirmation of SARS-CoV-2 (the…
On Oct. 14, 2021, Regeneron announced that the U.S. Food and Drug Administration (FDA) has accepted for priority…
On Oct. 14, 2021, Cepheid announced it had received the CE mark for Xpert Xpress CoV-2/Flu/RSV plus, a…
On Oct. 14, 2021, the World Health Organization (WHO) announced that the COVID-19 pandemic had reversed years of…
On Oct. 13, 2021, the Ministry of Health of the Democratic Republic of the Congo announced that vaccination…
On Oct. 12, 2021, Moderna announced that Gavi, the Vaccine Alliance had exercised its option to purchase an…
On Oct. 12, 2021, National Resilience announced a strategic collaboration with Children’s Hospital of Philadelphia (CHOP) to implement…
On Oct. 12, 2021, Inovio Pharmaceuticals announced online preprint publication in MedRxiv of Phase 1 clinical data on…
On Oct. 11, 2021, Merck and Ridgeback Biotherapeutics announced that Merck had submitted an Emergency Use Authorization (EUA)…
On Oct. 11, 2021, Inovio Pharmaceuticals announced that it had received authorization from Colombia’s INVIMA, to conduct the…
On Oct. 8, 2021, the Ministry of Health of the Democratic Republic of the Congo announced that a…
On Oct. 7, 2021, PerkinElmer announced that the U.S. Food and Drug Administration (FDA) has issued Emergency Use…
On Oct. 7, 2021, Vaxart announced that a Duke University-led study published in bioRxiv showed that Vaxart’s (investigational…